Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $9.79 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.13, a 927.27% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $4.27, a 70.81% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $14.63, a 1621.18% increase from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.85.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $33.90, a 1815.25% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $9.79 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | $4.27 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | ||||
| 2024-12-31 | $14.63 10-K · filed 2025-03-11 | ||||
| 2024-09-30 | $14.63 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $14.48 10-Q · filed 2024-08-06 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | ||||
| 2023-12-31 | $0.85 10-K · filed 2024-03-12 | ||||
| 2023-09-30 | $0.85 10-Q · filed 2023-11-07 | ||||
| 2021-12-31 | $33.90 10-K · filed 2023-03-07 | $1.13 10-K · filed 2022-03-08 | |||
| 2021-09-30 | $1.13 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $1.13 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $1.13 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $1.77 10-K · filed 2022-03-08 | ||||
| 2020-09-30 | $2.30 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $1.49 10-Q/A · filed 2020-08-31 | ||||
| 2020-03-31 | $0.11 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | $3.61 10-K · filed 2021-03-15 | ||||
| 2019-09-30 | $3.61 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | $3.92 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | $3.30 10-Q · filed 2019-05-09 | ||||
| 2018-12-31 | $2.50 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | $2.62 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | $3.40 10-Q · filed 2018-08-08 | ||||
| 2018-03-31 | $4.30 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $0.67 10-K · filed 2019-03-12 | ||||
| 2017-09-30 | $0.42 10-Q · filed 2017-11-08 | ||||
| 2017-06-30 | $0.39 10-Q · filed 2017-08-09 | ||||
| 2017-03-31 | $0.50 10-Q · filed 2017-05-09 | ||||
| 2016-12-31 | $1.43 10-K · filed 2018-03-12 | ||||
| 2016-09-30 | $1.39 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $1.00 10-Q · filed 2016-08-12 | ||||
| 2015-12-31 | $0.11 10-K · filed 2017-03-08 | ||||
| 2015-09-30 | $0.11 10-Q · filed 2015-11-10 | ||||
| 2015-06-30 | $0.11 10-Q · filed 2015-08-13 | ||||
| 2015-03-31 | $0.17 10-Q · filed 2015-05-13 | ||||
| 2014-12-31 | $0.11 10-K · filed 2016-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |